Page last updated: 2024-11-13

sodium cephalothin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23675321
CHEMBL ID1632
CHEBI ID3542
SCHEMBL ID148785
MeSH IDM0351072

Synonyms (119)

Synonym
AC-15529
smr000058777
EU-0100283
cephalothin sodium salt, 96.0-101.0%
cephalothin sodium salt
PRESTWICK_971
monosodium (6r,7r)-3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate acetate
sodium (6r,7r)-3-(acetoxymethyl)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cefalotina sodica
CHEBI:3542 ,
C08100
58-71-9
cefalotin sodium
cephalothin sodium
cephalothin sodium salt, bioreagent, suitable for cell culture
cefalothin
keflin (tn)
cefalotin sodium (jp17)
cephalothin sodium (usp)
D00907
cefalotina sodica [spanish]
einecs 200-394-6
ceporacin
toricelocin
sodium cephalothin
sodium cephalotin
7-(thiophene-2-acetamido)cephalosporanic acid sodium salt
monosodium (6r,7r)-3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate acetate (ester)
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6r,7r)-
cephalothin sodium w/ sodium chloride in plastic container
lilly 38253
cet injektionsfl
lovvalline injektionsfl
keflin n injektionsflaschen
synclotin
microtin
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(hydroxymethyl)-8-oxo-7-(2-(2-thienyl)acetamido)-, acetate, monosodium salt
keflin
cephalothin sodium w/ dextrose in plastic container
lospoven
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-((acetyloxy)methyl)-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6r-trans)-
keflin in plastic container
cephalothin sodium [usan]
tokiosarl ampullen
sodium cefalotin
cepovenin
cefalothine
seffin
MLS000069577 ,
SPECTRUM1500166
NCGC00093737-01
HMS2091A14
C 4520
HMS500E19
CHEMBL1632
nsc-756667
HMS1570O19
HMS1920K11
HMS3260J08
HMS2097O19
7-(thiophene-2-acetamido)cephalosporanic acid sodium
S4594
CCG-38923
nsc 756667
c22g6eyp8b ,
unii-c22g6eyp8b
cephalothin sodium [usan:usp]
LP00283
cephalothin sodium [usp impurity]
cephalothin sodium [usp monograph]
sodium (6r,7r)-3-(acetoxymethyl)-8-oxo-7-((2-thienylacetyl)amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
cefalotin sodium [jan]
cephalothin sodium [vandf]
cephalothin sodium [orange book]
monosodium (6r,7r)-3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate acetate (ester)
cefalotin sodium [mart.]
cefalotin sodium [ep monograph]
cephalothin sodium salt [mi]
cefalotin sodium [ep impurity]
cefalotin sodium [who-dd]
AKOS015896088
7-(2-thienylacetamido)cephalosporanic acid sodium salt
SCHEMBL148785
KS-1135
cephalothin sodium, cefalotin sodium
tox21_500283
C-2720
CS-4850
cephalotin sodium salt, antibiotic for culture media use only
NCGC00260968-01
sodium 7beta-(2-thienylacetamido)-3-acetoxymethyl-3-cephem-4-carboxylate
VUFGUVLLDPOSBC-XRZFDKQNSA-M
sodium (6r,7r)-3-acetoxymethyl-7-(thien-2-ylacetamido)ceph-3-em-4-carboxylate
sodium (6r, 7r)-3-acetoxymethyl-7-(thien-2-ylacetamido)ceph-3-em-4-carboxylate
sodium (6r,7r)-3-(acetoxymethyl)-8-oxo-7-(2-(thiophen-2-yl)acetamido)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
sodium;(6r,7r)-3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cephalothin (sodium)
HY-B1275
mfcd00072025
cefalotin sodium, european pharmacopoeia (ep) reference standard
(6r,7r)-3-acetoxymethyl-8-oxo-7-(2-thiophen-2-yl-acetylamino)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate sodium
cephalothin sodium, united states pharmacopeia (usp) reference standard
cefalotin for impurity b identification, european pharmacopoeia (ep) reference standard
HMS3714O19
DTXSID30891362 ,
cefalothin sodium salt,(s)
Q27106126
cefalotin for impurity b identification
sodium (6r,7r)-3-[(acetyloxy)methyl]-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
EN300-268484
cefalotin sodium (ep monograph)
cephalothin sodium w/dextrose in plastic container
cephalothin sodium (usan:usp)
cephalothin sodium (usp impurity)
dtxcid201030513
cefalotin sodium (mart.)
cephalothin sodium w/sodium chloride in plastic container
cefalotin sodium (ep impurity)
cephalothin sodium (usp monograph)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.96640.004023.8416100.0000AID485290; AID489007
Chain A, Beta-lactamaseEscherichia coli K-12Potency7.99600.044717.8581100.0000AID485294; AID485341
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency15.81140.140911.194039.8107AID2451
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency18.88760.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency17.90080.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency50.11870.100022.9075100.0000AID485364
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.95570.001530.607315,848.9004AID1224821
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency22.38720.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
DNA polymerase betaHomo sapiens (human)Potency21.45090.022421.010289.1251AID485314
DNA polymerase eta isoform 1Homo sapiens (human)Potency31.62280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency44.66840.050127.073689.1251AID588590
survival motor neuron protein isoform dHomo sapiens (human)Potency0.50120.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency2.81840.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1459
neuropeptide S receptor isoform AHomo sapiens (human)Potency31.62280.015812.3113615.5000AID1461
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
tyrosine-protein phosphatase non-receptor type 7 isoform 2Homo sapiens (human)IC50 (µMol)0.92000.100012.726563.0000AID521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamaseEnterobacter cloacaeKm15.40002.90006.43649.8000AID418990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID418992Ratio of Kcat to Km of Enterobacter cloacae beta-lactamase TEM-12009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1131960Antibacterial activity against Streptococcus pyogenes ATCC 8668 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID1131958Antibacterial activity against Staphylococcus aureus ATCC 6538P by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1131963Antibacterial activity against Proteus vulgaris ATCC 9484 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID418990Activity of Enterobacter cloacae beta-lactamase P992009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID1131961Antibacterial activity against Escherichia coli ATCC 25922-1 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID1131965Antibacterial activity against Staphylococcus aureus Smith infected in sc dosed mouse assessed as survival of host administered 1 hr and 5 hrs post challenge measured 72 hrs post challenge1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID418993Activity of Enterobacter cloacae beta-lactamase OXA-12009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1131962Antibacterial activity against Klebsiella pneumoniae ATCC 10031-2 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID1131959Antibacterial activity against penicillin G-resistant Staphylococcus aureus ATCC 14154 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1131964Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 by agar inclusion method1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
3-(3-Substituted prop-1-enyl)cephalosporins.
AID418994Ratio of Kcat to Km of Enterobacter cloacae beta-lactamase OXA-12009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID418987Activity of Enterobacter cloacae beta-lactamase TEM-12009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID418991Ratio of Kcat to Km of Enterobacter cloacae beta-lactamase P992009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Approaches to the simultaneous inactivation of metallo- and serine-beta-lactamases.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's0 (0.00)18.2507
2000's2 (15.38)29.6817
2010's9 (69.23)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.63 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]